Beneath the surface, a parallel track is forming. Ibogaine legislation at the state level carries 72% probability across at least three states before year's end, with Texas and Florida's veteran populations providing the political gravity that federal DEA opposition has so far neutralized at the NDAA conference level — where opposition testimony citing cardiac risk and Schedule I status is projected to hold. And a Tier 1 investigative piece documenting adverse events at unregulated ayahuasca retreats, including at least one death, carries a 71% probability of publication before September, a signal that the retreat industry is scaling faster than its safety culture can follow.
What is actually forming beneath all of this is a structural bifurcation in the psychedelic ecosystem — between the regulated pipeline, which is slowing as it encounters the genuine difficulty of FDA-grade evidence, and the unregulated frontier, which is accelerating into exactly the kind of harm that will harden the agency's posture for years. The highest positive trajectory available from here is not MDMA approval in 2026 — the evidence does not support that frame, and forcing it produces only disappointment and erosion of institutional trust. The genuine opening is this: a second Complete Response Letter, painful as it is, that forces a resubmission built on the massed-format Phase 3 data plus a credible cardiovascular safety package, arriving at FDA in 2027 with a file that advisory committee skeptics cannot dismiss on procedural grounds. That is the slower path. It is also the one that holds.
The human beings inside today's signal are waiting in a particular way — veterans whose treatment-resistant PTSD has not responded to SSRIs, families watching someone they love cycle through one failed protocol after another, clinicians in ketamine practices who are trying to hold a standard of care against a market that is moving faster than evidence. What is genuinely at stake is whether the regulatory friction that slows approval also becomes the thing that builds the trust that makes lasting access possible. The highest outcome for these real people is not a fast approval that collapses under post-market scrutiny — it is a rigorous path that arrives, holds, and opens a door that stays open.
Every authentic ceremony is a reclamation — of the body, the breath, the forgotten self. OOTW exists to hold space for that reclamation as the science arrives to name it.
The future does not wait for permission — it arrives through those who are ready.
73%
MDMA won't get FDA approval in 2026, gets rejection letter instead
The FDA (the US drug regulator) will reject MDMA as a treatment for PTSD in 2026 with a formal Complete Response Letter — a rejection that cites incomplete data on heart safety and addiction risk. This matters because MDMA's approval has been delayed repeatedly, and this prediction says the delays continue through all of next year.
→ MDMA approval is stuck and won't happen in 2026 — the regulator wants more safety proof than the company has provided.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
MDMA will not receive FDA approval in calendar year 2026 and will receive a second Complete Response Letter citing safety and abuse potential gaps.. Advisory committee skepticism is structural, not addressable by advocacy. Cardiovascular and abuse potential data files remain materially incomplete. Multi-agent consensus (fda_reviewer, dea_officer, neuropharmacologist) with only patient-advocacy voices dissenting. Resolution is clean: either an ap
72%
FDA will warn doctors about ketamine and suicidality risk before October 2026
The FDA will issue a formal safety communication warning doctors and hospitals about suicidality (suicide risk) linked to ketamine and its cousin esketamine (sold as Spravato) before October 2026. The agency will also tighten how these drugs can be prescribed (called REMS — Risk Evaluation and Mitigation Strategy). This matters because hospitals are increasingly using ketamine in emergency departments, and the FDA has spotted a signal that suicides are going up among people using it.
→ Ketamine's suicide risk is real enough that the FDA will formally warn doctors and add restrictions on how it's used.
Resolves: 2026-09-30 · USA
REGULATION
the precise call ▾
FDA will issue a formal safety communication on ketamine/esketamine and suicidality before October 2026, including updated REMS requirements for Spravato.. Post-market suicidality signals from ED utilization data create a clear regulatory obligation. REMS modification is the lowest-friction, most precedented agency response to live safety signals of this type. Falsifiable by presence or absence of a specific FDA safety communication with REMS language
68%
At least three states introduce ibogaine access bills for veterans by end of 2026
Before December 31, 2026, at least three US states will introduce (but not necessarily pass) new laws letting veterans access ibogaine — a plant-based psychedelic — outside the normal federal drug rules. This matters because the federal DEA (US drug enforcement agency) classifies ibogaine as illegal, but states can sometimes work around that. Veteran groups are pushing this hard because early evidence suggests ibogaine helps with PTSD and addiction.
→ Three states will try to carve out legal ibogaine access for veterans, even though the federal government still says it's illegal.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
At least three U.S. states will introduce ibogaine-specific veteran access legislation before December 31, 2026.. State-level legislative action avoids federal DEA scheduling constraints and is politically viable in high-veteran-population states (Texas, Florida). Momentum from existing pilot advocacy is documented. Falsifiable by a specific numerical threshold (3 states, introduced — not passed) with a hard ye
62%
MDMA PTSD study results published in major journal by September 2026
A peer-reviewed scientific journal will publish the full results of a large Phase 3 clinical trial (the final stage before approval) testing MDMA with a new compressed treatment schedule for PTSD by September 15, 2026. This matters because it shows whether the new, faster way of delivering MDMA therapy actually works — which could influence whether the FDA approves it.
→ The science on a new, faster MDMA therapy for PTSD will be published in a major journal by mid-2026.
Resolves: 2026-09-15 · Global
RESEARCH
the precise call ▾
Peer-reviewed Phase 3 data on MDMA-assisted massed exposure therapy for PTSD will be published in a indexed journal by September 15, 2026.. Massed format trials address prior treatment-duration objections and multi-site data convergence is reportedly strong. Publication is a discrete, verifiable event in a named journal with a clear date. Confidence trimmed from source estimate to account for publication scheduling uncertainty and possi
62%
Major news outlet investigates deaths at unregulated psychedelic retreats by September 2026
A top-tier news organization like the New York Times, Washington Post, or ProPublica will publish a deep-dive investigation of harm and deaths at illegal or unregulated psychedelic retreat centers before September 2026. This matters because psychedelic retreats are booming in places like Costa Rica and Jamaica, but there's almost no safety oversight, and people are dying — but the story hasn't hit mainstream media yet.
→ A major newspaper will expose deaths at illegal psychedelic retreats, bringing safety problems into public view.
Resolves: 2026-08-31 · USA
MEDIA
the precise call ▾
A Tier 1 outlet (NYT, WaPo, New Yorker, ProPublica, or equivalent) will publish an investigative piece on adverse events at unregulated psychedelic retreats — including at least one documented death — before September 2026.. Multiple journalists are reportedly developing this story. Retreat industry growth is outpacing safety culture, and high-profile harm incidents create compelling contrast with clinical trial framing. Falsifiable by specific outlet tier and the death-documentation criterion. Confidence reduced slight